Three More Months for Drug-Resistant Metastatic Colorectal Cancer: The SUNLIGHT Trial Gives an Old Drug Combination a New Place

When metastatic colorectal cancer no longer responds to earlier lines of treatment, physicians and patients are often not facing the question of whether there is still a miraculous new drug, but whether more time, and better-quality time, can be gained within a tolerable range of side effects. A large clinical trial recently brought back into discussion falls precisely into this realistic and difficult position: an unglamorous drug combination gained several additional months of survival for patients whose disease had already become difficult to treat.

The randomized phase 3 trial, named SUNLIGHT, compared trifluridine/tipiracil alone with trifluridine/tipiracil plus bevacizumab in refractory metastatic colorectal cancer. According to trial data published in the New England Journal of Medicine and indexed in PubMed, the study assigned 492 patients into two groups, with 246 people in each group; European Union clinical trial registry data also list the same enrollment size and describe the study as an open-label, randomized phase 3 comparative trial.

The results showed that the median overall survival in the group receiving bevacizumab in combination was 10.78 months, compared with 7.46 months in the trifluridine/tipiracil-alone group; the hazard ratio was 0.61, with a p value of less than 0.001. In other words, this was not a breakthrough in which tumors disappeared across the board, but a shift of the mortality risk curve in a favorable direction in the later-line treatment setting. For many patients who have already received at least several treatments, such a difference is enough to influence treatment sequencing and clinical discussion.

Trifluridine/tipiracil is an oral chemotherapy drug combination that has been used in later-line treatment for metastatic colorectal cancer; bevacizumab is an anti-angiogenic drug that inhibits VEGF-related pathways, blocking part of a tumor’s ability to obtain a blood supply. The significance of SUNLIGHT is that it did not invent a new mechanism from scratch, but re-examined the value of combining existing drugs at a specific stage of disease.

A research commentary in Nature Reviews Clinical Oncology noted that SUNLIGHT randomly assigned patients with unresectable colon or rectal adenocarcinoma in a 1:1 ratio, with overall survival as the primary endpoint. This also makes the results more closely aligned with clinical decision-making than response rate alone: in later-line treatment for advanced cancer, tumor shrinkage on imaging is certainly important, but what patients truly face is time, symptom control, treatment burden, and the next choice.

However, these data also need to be read in light of their limitations. The trial used an open-label design, meaning patients and investigators knew the treatment assignment; participants’ characteristics, number of prior lines of therapy, and physical condition also affect whether the results can be directly applied to every patient. European Union registry data show that the trial’s global end date was September 12, 2023, and the results have entered more complete registry and journal records, but whether an individual patient is suitable for use still depends on factors such as bleeding risk, blood pressure control, risk of bowel perforation, overall performance status, and prior treatment history.

Background Context

In recent years, cancer treatment news has often been dominated by immunotherapy, cell therapy, and AI drug discovery, but in everyday colorectal cancer practice, progress often comes from more refined combinations and sequencing. The SUNLIGHT trial reminds people that “progress” in later-line treatment does not always appear in dramatic language; sometimes it is an addition confirmed by a randomized trial, giving patients who have already reached the later stages of treatment one more option that can be seriously discussed.